罗格列酮治疗非酒精性脂肪性肝病的研究-内科学(消化)专业毕业论文.docxVIP

温州医学院硕士学位论文 温州医学院硕士学位论文 肪肝患者存在胰岛素抵抗，治疗后治疗组胰岛素抵抗指数明显增高(PO．05)， 而对照组改变不明显(PO．05)；脂肪肝患者肝纤维谱水平明显高于正常组(P O．05)。提示存在肝脏纤维化；治疗组经罗格列酮治疗半年后，其血糖、血脂、 肝纤维谱较治疗前明显下降，(PO．05)，其肝脏CT值明显上升(PO．05)。而 对照组改变不明显(PO．05)，甚至血清甘油三脂较前增高(PO．05)。 结论：过氧化体增殖物激活受体(PPAR)一y激动剂一噻唑烷二酮类(TzD)：马 来酸罗格列酮是一种新型的胰岛素增敏剂，用它治疗非酒精性脂肪性肝病，不但 可以改善胰岛素抵抗，同时具有调节血脂，改善肝脏纤维化，更重要的是能减少肝 脏的脂肪沉积，并且副作用不明显。 关键词： 非酒精性脂肪性肝病罗格列酮 温州医学院硕士学位论文The 温州医学院硕士学位论文 The Efficacy of ROsigI．tazOne in Treating Non-alcoholic Fa埘Liver Disease Abstract OBJECTIVE：Recent studies have demonstrated that the treatment with rosiglitazone reduces hepatic fibrosis．The aim of this study was to elucidate the mechanism and the efficacy of rosiglitazone in treating non．alcoholic fatty Iiver disease， METHODS：We conducted a triaI．nvolving 20 healthy people as controI(defined as nOrmaJ group)and 62 patients with non—alcoholic fatty Iiver disease who are diagnosed according to“guidelines on the diagnosis of non．alcoholic fatty Iiver disease”established by Working Group Of Fat Liver And Alcoholic Liver on behalf of Chinese MedicaI Association．Every patient undergoes computed tomography(CT)scan and is proved that there js diffusely but not Iocal fatty infiltration in Iiver．Blood for measurement of fasting plasma glucose、jnsulin、 triglyceride(TG)、cholesteroJ、 ALT，AS丁and marks of hepatic fibrosis js withdraw from elbow vein jn alI subjects after at Ieast ten hours fasting in the early morning．1ndex of insulin resistance is calculated according to the formula： fasting glucose(millimoles per liter)／fasting insulin(millimoles per liter)．Sixty．two patients are randomized into two groups：twenty—one are assigned to control group(aged 59．2+／-2．5 years．12 males and 9 females)and fo咖．one are assigned to treatment group(aged 57．1+／-1．9 vears。21 males and 20 females)．There are eight moderate and thirteen serious fatty liver patients in controI group while twenty moderate and twenty—one serious fatty Iiver patients in fatfy liver group．There are no significant differences